Skip to main content
OpenTrials
Completed

NCT Number: NCT06568224

Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery. However, responses to treatments are variable and relapse is common, with no single agent being consistently effective.

Objective: To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa .

Methods: Investigators reported a series of cases of patients who received oral mesalazine(1g qid) for hidradenitis suppurativa in our institution between May 2020 and September 2023. A total of 27 patients, 22 in the mild to moderate group and 5 in the severe group, were included in this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hidradenitis Suppurativa Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Jiangsu Provincial People's Hospital

Nanjing, 210029, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recurrent painful or suppurative lesions
  • Typical clinical manifestations: the distribution of apocrine sweat glands is deep in painful nodules, abscesses, sinuses, scars;

Exclusion criteria

  • Severe neurological and psychiatric diseases
  • Tumor diseases
  • Pregnant women in lactation period

Treatment and study plan

Mesalazine

Drug

oral mesalazine 1g qid

Primary outcomes

  1. Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis

    Time frame: Three and a half years

    We registered the number of patients who achieved HiSCR（%）.

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Registry information

Official study title

Treatment for Hidradenitis Suppurativa

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Aug 23, 2024
Registry last updated
Sep 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.